Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prodrugs in genetic chemoradiotherapy.
Patterson AV, Saunders MP, Greco O. Patterson AV, et al. Among authors: saunders mp. Curr Pharm Des. 2003;9(26):2131-54. doi: 10.2174/1381612033454117. Curr Pharm Des. 2003. PMID: 14529410 Review.
Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-Fluorouracil.
Chatterjee S, Naeli P, Onar O, Simms N, Garzia A, Hackett A, Coyle K, Harris Snell P, McGirr T, Sawant TN, Dang K, Stoichkova ZV, Azam Y, Saunders MP, Braun M, Alain T, Tuschl T, McDade SS, Longley DB, Gkogkas CG, Adrain C, Knight JRP, Jafarnejad SM. Chatterjee S, et al. Among authors: saunders mp. Nucleic Acids Res. 2024 Nov 11;52(20):12534-12548. doi: 10.1093/nar/gkae849. Nucleic Acids Res. 2024. PMID: 39351862 Free PMC article.
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.
Gögenur M, Rosen AW, Iveson T, Kerr RS, Saunders MP, Cassidy J, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, Pearson S, Boyd KA, Briggs AH, Waterston A, Medley L, Ellis R, Dhadda AS, Harrison M, Falk S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Cunningham D, Hickish T, Gollins S, Wasan HS, Kelly C, Gögenur I, Holländer NH. Gögenur M, et al. Among authors: saunders mp. JAMA Surg. 2024 Aug 1;159(8):865-871. doi: 10.1001/jamasurg.2024.1555. JAMA Surg. 2024. PMID: 38865139 Clinical Trial.
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Frei AL, McGuigan A, Sinha RRAK, Jabbar F, Gneo L, Tomasevic T, Harkin A, Iveson T, Saunders MP, Oien KA, Maka N, Pezzella F, Campo L, Browne M, Glaire M, Kildal W, Danielsen HE, Hay J, Edwards J, Sansom O, Kelly C, Tomlinson I, Kerr R, Kerr D, Domingo E; TransSCOT consortium; Church DN, Koelzer VH. Frei AL, et al. Among authors: saunders mp. Lancet Oncol. 2024 Feb;25(2):198-211. doi: 10.1016/S1470-2045(23)00560-0. Lancet Oncol. 2024. PMID: 38301689 Free article.
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, Jones GN, Willis SE, Petrone M, Silva C, Thway K, Bunce C, Roxanis I, Nenclares P, Wilkins A, McLaughlin M, Jayme-Laiche A, Benafif S, Nintos G, Kwatra V, Grove L, Mansfield D, Proszek P, Martin P, Moore L, Swales KE, Banerji U, Saunders MP, Spicer J, Forster MD, Harrington KJ. Dillon MT, et al. Among authors: saunders mp. J Clin Invest. 2024 Jan 16;134(2):e175369. doi: 10.1172/JCI175369. J Clin Invest. 2024. PMID: 37934611 Free PMC article. Clinical Trial.
SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
Saunders MP, Iype R, Kelly C, Crosby J, Kerr R, Harkin A, Allan K, McQueen J, Pearson SR, Cassidy J, Medley LC, Raouf S, Harrison M, Brewster A, Rees C, Ellis R, Thomas AL, Churn M, Iveson T, Maka N. Saunders MP, et al. Clin Colorectal Cancer. 2023 Jun;22(2):231-237. doi: 10.1016/j.clcc.2023.02.005. Epub 2023 Feb 22. Clin Colorectal Cancer. 2023. PMID: 36967267 Clinical Trial.
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T, Falcone A, Shparyk Y, Moiseenko F, Polo-Marques E, Csöszi T, Campos-Bragagnoli A, Liposits G, Chmielowska E, Aubel P, Martín L, Fougeray R, Amellal N, Saunders MP. André T, et al. Among authors: saunders mp. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):133-144. doi: 10.1016/S2468-1253(22)00334-X. Epub 2022 Dec 2. Lancet Gastroenterol Hepatol. 2023. PMID: 36470291 Clinical Trial.
111 results